Synonyms: (R)-crizotinib | PF 2341066 | PF-02341066 | PF-2341066 | PF2341066 | Xalkori®
crizotinib is an approved drug (FDA (2011), EMA (2012))
Compound class:
Synthetic organic
Comment: Critzotinib is a Type-1 kinase inhibitor and was first approved by the FDA in 2011. It inhibits ALK, cMET and ROS1 receptor tyrosine kinases. Critzotinib is a chiral molecule that exploits the three-dimensional space of the ATP pocket to achieve optimal potency and selectivity [6]. The R-enantiomer as shown here exhibits better potency than the either the racemate or S-isomer and the approved drug should contain only the R-enantiomer.
Pfizer developed the 3rd generation ALK inhibitor lorlatinib as a follow-up to critzotinib, and this new drug has been reported to outperfom its predecessor in lung cancer. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2011), EMA (2012)) |
IUPAC Name |
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine |
International Nonproprietary Names | |
INN number | INN |
9301 | crizotinib |
Synonyms |
(R)-crizotinib | PF 2341066 | PF-02341066 | PF-2341066 | PF2341066 | Xalkori® |
Database Links | |
CAS Registry No. | 877399-52-5 |
ChEMBL Ligand | CHEMBL601719 |
DrugCentral Ligand | 4187 |
GtoPdb PubChem SID | 178101602 |
PubChem CID | 11626560 |
RCSB PDB Ligand | VGH |
Search Google for chemical match using the InChIKey | KTEIFNKAUNYNJU-GFCCVEGCSA-N |
Search Google for chemicals with the same backbone | KTEIFNKAUNYNJU |
Search PubMed clinical trials | crizotinib |
Search PubMed titles | crizotinib |
Search PubMed titles/abstracts | crizotinib |
SynPHARM |
79022 (in complex with anaplastic lymphoma receptor tyrosine kinase) 78753 (in complex with MET proto-oncogene, receptor tyrosine kinase) 79023 (in complex with MET proto-oncogene, receptor tyrosine kinase) |
UniChem Compound Search for chemical match using the InChIKey | KTEIFNKAUNYNJU-GFCCVEGCSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | KTEIFNKAUNYNJU-GFCCVEGCSA-N |
Wikipedia | Crizotinib |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Crizotinib (links to external site)
Cat. No. 4368 |